AU2601895A - Modified insulin-like growth factors - Google Patents

Modified insulin-like growth factors

Info

Publication number
AU2601895A
AU2601895A AU26018/95A AU2601895A AU2601895A AU 2601895 A AU2601895 A AU 2601895A AU 26018/95 A AU26018/95 A AU 26018/95A AU 2601895 A AU2601895 A AU 2601895A AU 2601895 A AU2601895 A AU 2601895A
Authority
AU
Australia
Prior art keywords
growth factors
modified insulin
insulin
modified
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU26018/95A
Other languages
English (en)
Inventor
George N. Cox
Christine Ko
Martin J McDermott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Boulder Inc
Original Assignee
Amgen Boulder Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Boulder Inc filed Critical Amgen Boulder Inc
Publication of AU2601895A publication Critical patent/AU2601895A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU26018/95A 1994-05-24 1995-05-24 Modified insulin-like growth factors Abandoned AU2601895A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24827394A 1994-05-24 1994-05-24
US248273 1994-05-24
PCT/US1995/006540 WO1995032003A1 (fr) 1994-05-24 1995-05-24 Facteurs de croissance proches de l'insuline modifies

Publications (1)

Publication Number Publication Date
AU2601895A true AU2601895A (en) 1995-12-18

Family

ID=22938406

Family Applications (1)

Application Number Title Priority Date Filing Date
AU26018/95A Abandoned AU2601895A (en) 1994-05-24 1995-05-24 Modified insulin-like growth factors

Country Status (5)

Country Link
EP (1) EP0756494A1 (fr)
JP (1) JPH10500693A (fr)
AU (1) AU2601895A (fr)
CA (1) CA2190752A1 (fr)
WO (1) WO1995032003A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US6870033B1 (en) 1997-02-21 2005-03-22 Genentech, Inc. Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US7270809B2 (en) 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
US7005504B2 (en) 1998-01-22 2006-02-28 Genentech, Inc. Antibody fragment-peg conjugates
US6468532B1 (en) 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
AU3548999A (en) 1998-04-03 1999-10-25 Chiron Corporation Use of igfi for treating articular cartilage disorders
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
CA2359345A1 (fr) * 1999-01-14 2000-07-20 Bolder Biotechnology, Inc. Techniques permettant de produire des proteines contenant des residus cysteine libres
DE60022336T2 (de) 1999-04-02 2006-06-22 Ajinomoto Co., Inc. Vefahren zur herstellung von peptiduntereinheiten aus polymer-proteinen
IL152804A0 (en) * 2000-05-16 2003-06-24 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
AU2002335657A1 (en) 2001-08-24 2003-03-10 Neuronz Biosciences, Inc. Neural regeneration peptide and methods for their use in treatment of brain damage
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
JP5207590B2 (ja) 2002-12-26 2013-06-12 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド 増強された生物学的能力を有するインターフェロン−βのポリマー結合体
EP1674113A1 (fr) * 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugués de l'IGF-1 et du poly(éthylène glycol)
US8293708B2 (en) 2005-08-30 2012-10-23 Novo Nordisk Health Care A/G Liquid formulations N-terminal serine of pegylated growth hormone
WO2007041614A2 (fr) 2005-10-03 2007-04-12 Bolder Biotechnology, Inc. Inhibiteurs de vegf a action prolongee et leurs methodes d'utilisation
KR101459789B1 (ko) 2006-06-09 2014-11-07 노파르티스 아게 안정화된 인슐린-유사 성장 인자 폴리펩티드
BRPI0713963A2 (pt) 2006-07-07 2012-11-27 Novo Nordisk Healthcare Ag conjugados de proteìna e métodos para sua preparação
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
JP4958975B2 (ja) 2006-08-31 2012-06-20 エフ．ホフマン−ラ ロシュ アーゲー インスリン様増殖因子ｉの製造方法
WO2008076933A2 (fr) 2006-12-14 2008-06-26 Bolder Biotechnology, Inc. Protéines et peptides à action prolongée et procédés de production et d'utilisation de ces derniers
WO2009051844A1 (fr) 2007-10-17 2009-04-23 Neuren Pharmaceuticals Limited Analogues synthétiques de peptides de régénération neurale
JP5173018B2 (ja) * 2008-04-03 2013-03-27 エフ．ホフマン−ラ ロシュ アーゲー 神経筋障害の処置のためのｐｅｇ化ｉｇｆ−ｉ変異体の使用
CA2786340C (fr) * 2010-02-11 2017-08-22 F. Hoffmann-La Roche Ag Conjugues de l'igf-i et du poly(ethylene glycol)
EP2571992B1 (fr) 2010-05-21 2018-04-25 Merrimack Pharmaceuticals, Inc. Protéines hybrides bispécifiques
US9708366B2 (en) 2011-01-27 2017-07-18 Neuren Pharmaceuticals Ltd. Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate
CN108367048B (zh) 2015-10-02 2022-08-12 银溪制药股份有限公司 用于组织修复的双特异性治疗性蛋白质
EP3946413A4 (fr) * 2019-04-03 2023-01-11 Technical University of Denmark Conjugués de protéine de facteur neurotrophique et modes de réalisation associés

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
ATE240740T1 (de) * 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
EP0679095A1 (fr) * 1992-11-25 1995-11-02 Amgen Boulder Inc. Facteur de croissance insulinoide modifie
AU6626794A (en) * 1993-04-07 1994-10-24 Amgen Boulder Inc. Methods of using insulin-like growth factor binding proteins

Also Published As

Publication number Publication date
EP0756494A1 (fr) 1997-02-05
WO1995032003A1 (fr) 1995-11-30
JPH10500693A (ja) 1998-01-20
CA2190752A1 (fr) 1995-11-30

Similar Documents

Publication Publication Date Title
AU2601895A (en) Modified insulin-like growth factors
AU676586B2 (en) Bone transporter
AU4642396A (en) Retroilluminating indirect gonioprism
AU3304795A (en) Bisresorcinyltriazines
AU2832295A (en) Cytoanalyzer
AU3304995A (en) 2-Hydroxyphenyltriazines
AU3265495A (en) Plant growth promoter
AU3028995A (en) Binding agent for growth factor
AU4538297A (en) Inositolglycans having insulin-like action
AU2837895A (en) Thiazine- or thiazepine-derivatives
AU3011497A (en) Novel human growth factors
AU4131596A (en) Polyglycomers
AU4044795A (en) Handleset
AU3921993A (en) Novel antler-derived bone growth factors
AU2375495A (en) Prosthesis
AU2653095A (en) Fibroblast growth factor-14
AU3207195A (en) Growth stimulating factors
AU2308295A (en) Heterocyclylbenzonitriles
AU1963395A (en) Boom-structure
AU4029295A (en) Thienopyridones
AU4590996A (en) Boekomslag
AU3446995A (en) Biodestumping
AU3166095A (en) Benzylimidazopyridines
AU2411395A (en) Hydrocopter
AU1603595A (en) Meso-azanoradamantanes